載入...
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Progress in the development of new therapies for cystic fibrosis (CF) has benefitted from therapeutically responsive biomarkers to streamline drug development. Paradoxically, these response biomarkers have proven to be essential even in the presence of data demonstrating a lack of correlation with c...
Na minha lista:
| 發表在: | Trends Mol Med |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708517/ https://ncbi.nlm.nih.gov/pubmed/32868171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmed.2020.08.002 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|